Alzheimer’s Disease – Unmet Need – Detailed, Expanded Analysis (US & EU) Agitation in Alzheimer’s Disease

In addition to cognitive symptoms, the pharmaceutical industry is focusing on treating the neuropsychiatric symptoms of Alzheimer’s disease (AD), including agitation. According to Clarivate epidemiology, agitation affects the majority of patients diagnosed with AD and comprises a constellation of disruptive symptoms for patients and their families. With competing brands from Lundbeck / Otsuka, Axsome Therapeutics, Avanir / Otsuka, and Intra-Cellular Therapies (among others) poised to enter the market beginning in 2023 and with blockbuster sales at stake, understanding the drivers of clinical decision-making in agitation and prescriber perceptions of the risk / benefit profiles of today’s off-label generic options will help identify levers for new product positioning and differentiation in this evolving market.


  • What are the treatment drivers and goals for agitation in AD?
  • What attributes drive decision-making in agitation in AD, which have limited impact, and which are hidden opportunities?
  • How do current off-label treatments perform on these attributes?
  • Based on a conjoint analysis and TPP simulation, what trade-offs across key clinical attributes and price are neurologists willing to make for a hypothetical new drug to treat agitation in AD?


Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 32 European neurologists fielded in February 2022

Key companies: Otsuka / Lundbeck, Avanir / Otsuka, Axsome Therapeutics, Intra-Cellular Therapies 

Key drugs: Quetiapine, risperidone, olanzapine, aripiprazole, sertraline, lorazepam, gabapentin, Rexulti, AVP-786, AXS-05, ITI-1284 ODT-SL

Table of contents

launch Related Market Assessment Reports